Allergan's Sanctura IP Appeal Turned Away By High Court

Law360, New York (October 15, 2012, 2:41 PM EDT) -- The U.S. Supreme Court on Monday refused to take up Allergan Inc.'s appeal of a ruling that invalidated patents covering the company's overactive bladder medication Sanctura XR, which Allergan had accused several generics companies of infringing.

By denying Allergan's petition, the high court effectively keeps in place an order handed down in June by the Federal Circuit, which affirmed U.S. District Judge Gregory M. Sleet's issuing of a judgment in favor of three generic-drug makers — Perrigo Co.'s Paddock Laboratories Inc., Novartis AG's Sandoz Inc. and...
To view the full article, register now.